Study reports senolytic ABT-263 attenuates senescence-induced stromal remodeling

Researchers reported that cellular senescence in prostate cells drives fibroblast activation via TGF-β1, which can be mitigated in vitro and in vivo by the senolytic ABT-263.

A study published in Neoplasia reported that cellular senescence in human and mouse prostate epithelial cells drives extracellular matrix (ECM) remodeling and fibroblast activation in the surrounding stroma.

Using a Pten conditional knockout mouse model and in vitro RM1 cells, researchers demonstrated that senescent epithelial cells acquire a fibrogenic secretory phenotype characterized by increased TGF-β1 secretion.

This secretory program reprogrammed NIH/3T3 fibroblasts into an ECM-remodeling, cancer-associated fibroblast (CAF)-like state via the TGF-β/SMAD2 signaling pathway.

Treatment with the senolytic agent ABT-263 reduced the senescent cell population and decreased TGF-β1 secretion, which subsequently diminished the fibroblast-remodeling activity.

The study identifies epithelial senescence-associated signaling as a direct driver of stromal remodeling and localized fibrosis.

It provides a clear mechanistic rationale for using senolytic interventions to halt or reverse tissue-remodeling cascades, rather than just clearing senescent cells for general survival metrics.

These findings bolster the preclinical validation of senolytic therapies, specifically supporting the therapeutic strategy of targeting cellular senescence to arrest tissue aging and fibrotic remodeling.

The research emphasizes the potential of Bcl-2 family inhibition (such as ABT-263/navitoclax) in managing microenvironmental tissue dysfunction.

Future research will likely investigate whether these senolytic-mediated microenvironmental improvements translate to other, non-oncological age-related fibrotic indications.